Advanced Plasma Items launches its fresh TriClean Pro air sanitizer Applied Science Products.

Related StoriesNew test capable of detecting all infections that affect people and animalsModelling the biological mesoscale: an interview with Professor Art OlsonUsing NMR to study influenza and TB: an interview with Dr. Tim Cross Kenneth Wood, CEO of Applied Science Products, noted The efficiency of the TriClean Pro in removing and destroying VOCs and microorganisms from the environment coupled with its portability make it a perfect product for a number of applications and settings where indoor air quality is a problem. With increasing incidences of multi-drug resistant bacteria infections and viral outbreaks, the TriClean Pro can offer a targeted approach to help address airborne contamination in locations such as healthcare services, including hospitals, doctors’ offices, and nursing house/assisted living facilities, athletic locker rooms, corporate offices, day care and attention centers, veterinary and kennel facilities, schools, motels and hotels, and mold contaminated structures .‘Translating these fresh discoveries and technology into personalized patient care offers the possibility of better survival, much less toxicity, disease avoidance, improved quality of life, and lower health-treatment costs.’ By determining the most promising areas of research, ASH hopes to work with federal agencies and various other stakeholders to prioritize and leverage limited resources with the goal of supporting research which will ultimately improve patient treatment.

Abbott, Sucampo receive Japanese approval for AMITIZA Sucampo Pharmaceuticals, Inc. and Abbott today announced that Sucampo Pharma, Ltd. Related StoriesScripps Florida scientists win $2.4 million to increase development of new pain therapies ‘We are very very happy to receive Japan’s first-ever acceptance for a prescription drugs for chronic constipation as it helps us achieve our objective of getting medicines with novel mechanisms of action to individuals with unmet medical needs on a global basis,’ stated Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo’s Chairman and Chief Executive Officer.